Cytotrait Limited Secures £3.4m Seed Funding to Advance Crop Technology

Cytotrait Limited, a Manchester-based biotechnology company, has successfully closed a £3.4m seed funding round. The company specialises in developing novel traits for food and agriculture through its proprietary Mutant Organelle Selection System (MOSS) technology.

Incorporated on 24 October 2023, Cytotrait is addressing global challenges in food security and sustainable agriculture. The company's unique approach involves reprogramming chloroplast and mitochondrial genomes to enhance crop yields, resilience, and introduce valuable food traits. Its technology targets major crops such as wheat, maize, potato, and canola, with a focus on European and North American markets. According to its LinkedIn profile, Cytotrait has a team of 4 employees, while its latest accounts noted 2 employees. Financial metrics such as revenue and profit/loss have not been disclosed.

The seed round, estimated at £3.4m, saw its shares allotted on 1 April 2026, with the filing date on 8 April 2026. The specific investors participating in this round have not been publicly disclosed, nor have details regarding the company's valuation at this stage. This marks Cytotrait Limited's first disclosed funding round since its incorporation. The company recently strengthened its leadership team with the appointment of Dr Timothy Brears and Cassandra Clare Doherty as directors on 27 February 2026, shortly before the funding allotment.

This funding round for Cytotrait Limited comes at a time when the UK's biotechnology and agritech sectors are navigating a complex investment landscape. In 2025, the UK biotech sector raised £1.9 billion in equity financing, marking a 49% decrease from 2024, with venture capital accounting for £1.8 billion, a 13.2% decrease year-on-year. This decline was largely driven by a concentration of funding into a small number of large rounds, with mid-sized scale-up financings seeing no recovery. Early-stage investment also weakened, with seed rounds representing 28% of all deals but only 5.6% of total capital in 2025, down from 30% of deals and 8% of capital in 2024.

Despite these challenges, the UK maintained its position as Europe's leading national biotech market in 2025, attracting 30% of all European venture financing. There were also positive signs towards the end of 2025, with the fourth quarter recording 22 completed deals, the highest quarterly deal count of the year, suggesting a revitalised appetite for the broader SME ecosystem and improved investor sentiment heading into 2026.

The agritech sector, in particular, continues to see significant government support and strategic interest. Initiatives such as Innovate UK grants and the Farming Innovation Programme (FIP) are actively backing innovation in the sector. The Genetic Technology (Precision Breeding) Regulations 2025, which came into effect in November 2025, are expected to facilitate a ramp-up in trials and partnerships for precision-bred plants in 2026, directly supporting food supply resilience. Early-stage companies in agritech, like Cytotrait, are a significant part of the landscape, with 52% of active UK agritech companies being at the Seed stage. Recent examples of early-stage funding in related areas include London-based agricultural biotechnology company Resurrect Bio securing an initial $8.1 million Series A round in February 2026, and Semarion raising £2.9 million in March 2026. This indicates continued investor interest in innovative solutions addressing crop resilience and food security, aligning with Cytotrait's mission.